Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akira Okazaki is active.

Publication


Featured researches published by Akira Okazaki.


Journal of Biological Chemistry | 1996

In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines

Sonoko Masuda; Valarie Byford; Richard Kremer; H. L. J. Makin; Noboru Kubodera; Yasuho Nishii; Akira Okazaki; Toshio Okano; Tadashi Kobayashi; Glenville Jones

Using four cultured cell models representing liver, keratinocyte, and osteoblast, we have demonstrated that the vitamin D analog, 22-oxacalcitriol is degraded into a variety of hydroxylated and side chain truncated metabolites. Four of these metabolic products have been rigorously identified by high pressure liquid chromatography, diode array spectrophotometry, and gas chromatography-mass spectrometry analysis as 24-hydroxylated and 26-hydroxylated derivatives as well as the cleaved molecules, hexanor-1α,20-dihydroxyvitamin D and hexanor-20-oxo-1α-hydroxyvitamin D. Comparison with chemically synthesized standards has revealed the stereochemistry of the biological products. Although differences exist in the amounts of products formed with the different cell types, it is apparent that 22-oxacalcitriol is subject to metabolism by both vitamin D-inducible and noninducible enzymes. Time course studies suggest that the truncated 20-alcohol is derived from a side chain hydroxylated molecule via a hemiacetal intermediate and the 20-oxo derivative is likely formed from the 20-alcohol. Biological activity measurements of the metabolites identified in our studies are consistent with the view that these are catabolites and that the biological activity of 22-oxacalcitriol is due to the parent compound. These results are also consistent with recent findings of others that the biliary excretory form of 22-oxacalcitriol is a glucuronide ester of the truncated 20-alcohol.


Journal of Pharmacology and Experimental Therapeutics | 1997

Mechanism for the nonlinear pharmacokinetics of erythropoietin in Rats

Motohiro Kato; Hiroshi Kamiyama; Akira Okazaki; Kenji Kumaki; Yukio Kato; Yuichi Sugiyama


Drug Metabolism and Disposition | 1998

Pharmacokinetics of erythropoietin in genetically anemic mice.

Motohiro Kato; Kumi Miura; Hiroshi Kamiyama; Akira Okazaki; Kenji Kumaki; Yukio Kato; Yuichi Sugiyama


Chemical & Pharmaceutical Bulletin | 1985

Bioavailability of Pyridoxal Phosphate from Enteric-Coated Tablets. I. Apparent Critical Dissolution pH and Bioavailability of Commercial Products in Humans

Nahoko Kaniwa; Hiroyasu Ogata; Nobuo Aoyagi; Masanobu Koibuchi; Toshio Shibazaki; Akira Ejima; Shigeru Takanashi; Hiroshi Kamiyama; Hidetaka Suzuki; Yoshikazu Hinohara; Hideki Nakano; Akira Okazaki; Tadao Fujikura; Kazuo Igusa; Sadao Bessho


Drug Metabolism and Disposition | 1997

IMMUNOLOGICAL RESPONSE TO REPEATED ADMINISTRATION OF RECOMBINANT HUMAN ERYTHROPOIETIN IN RATS Biphasic Effect on Its Pharmacokinetics

Motohiro Kato; Kumi Miura; Hiroshi Kamiyama; Akira Okazaki; Kenji Kumaki; Yukio Kato; Yuichi Sugiyama


Chemical & Pharmaceutical Bulletin | 1985

Bioavailability of Pyridoxal Phosphate from Enteric-Coated Tablets. III. Correlations between Bioavailability in Humans and Beagle Dogs and between Bioavailability in Humans and in Vitro Dissolution Rates

Nahoko Kaniwa; Hiroyasu Ogata; Nobuo Aoyagi; Masanobu Koibuchi; Toshio Shibazaki; Akira Ejima; Shigeru Takanashi; Hiroshi Kamiyama; Hidetaka Suzuki; Yoshikazu Hinohara; Hideki Nakano; Akira Okazaki; Tadao Fujikura; Kazuo Igusa; Sadao Bessho


Japanese Journal of Pharmacology | 1987

Antithrombotic and ulcerogenic effects of fenflumizole, a new anti-inflammatory imidazole derivative, in rats.

Hiroyuki Nabata; Masako Uchino; Akira Okazaki; Tamotsu Yamazaki; Kazushige Sakai


Archive | 1979

Terephthalic acid monoamide derivatives, process for preparing the same, and an anti-allergic agent prepared from the same

Sakae Takaku; Takashi Mori; Yasushi Murakami; Yoshiyuki Ohsugi; Shigeyuki Kataoka; Yasuhisa Takeda; Takashi Matsuno; Yoshimitsu Iida; Akiko Ariga; Akira Okazaki; Kazuo Igusa; Toshichika Ogasawara; Minoru Shindo


Drug Metabolism and Pharmacokinetics | 1995

Disposition of Q-35(1): Absorption and Excretion after Single Administration of 14C-Q-35 in Rats

Masaki Ishigai; Toshito Nakagawa; Satofumi Iida; Tsuneo Okutomi; Kazumi Ohkubo; Akira Okazaki


Drug Metabolism and Pharmacokinetics | 1995

The Pharmacokinetics of Large Molecules after Subcutaneous Administration

Motohiro Kato; Kumi Miura; Hiroshi Kamiyama; Akira Okazaki

Collaboration


Dive into the Akira Okazaki's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jun Amano

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Kazumi Ohkubo

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Ken Okano

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Yuka Hiramatsu

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Masaki Ishigai

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hidetaka Suzuki

Chugai Pharmaceutical Co.

View shared research outputs
Researchain Logo
Decentralizing Knowledge